Perimenopause, Menopause and HRT: Symptoms, Benefits and Risks
Key message: Perimenopause can affect periods, temperature control, sleep, mood, sex and bladder or vaginal health. HRT is…
Key message: Perimenopause can affect periods, temperature control, sleep, mood, sex and bladder or vaginal health. HRT is effective for many symptoms and should be individualised by age, health, uterus status, risk factors and preferences.
Get urgent help: Seek urgent care for chest pain, sudden breathlessness, coughing blood, one swollen painful leg, stroke symptoms or severe allergic reaction. Any bleeding after 12 months without a natural period needs prompt assessment; heavy bleeding or faintness is urgent.
What are perimenopause and menopause?
Perimenopause is the transition before the final period, when cycles and symptoms fluctuate. Menopause is diagnosed retrospectively after 12 months without a natural period when no other cause applies.
In people aged 45 or over with typical symptoms, diagnosis is often clinical and routine hormone testing is usually unnecessary.
What symptoms can occur?
- Hot flushes and night sweats.
- Sleep disturbance, fatigue and concentration difficulty.
- Mood change, anxiety or worsening migraine.
- Irregular, heavier or lighter periods.
- Vaginal dryness, pain during sex, urinary urgency or recurrent urinary symptoms.
- Joint aches, skin/hair change and reduced sexual desire.
What should be assessed before treatment?
- Bleeding pattern and contraception.
- Personal and family history of breast, ovarian or endometrial cancer.
- Blood clots, stroke, migraine, liver disease and cardiovascular risk.
- Blood pressure, medicines, smoking and alcohol.
- Uterus status and previous hysterectomy.
- Bone health and risk of osteoporosis.
What does HRT contain?
Systemic HRT uses estrogen for symptoms. A person with a uterus also needs a progestogen to protect the endometrium; after total hysterectomy, estrogen-only HRT is usually used unless another reason changes the plan.
Estrogen can be given as a tablet, patch, gel or spray. Progestogen may be oral, transdermal in some preparations or delivered by a suitable intrauterine system.
What are the benefits?
- Most effective treatment for hot flushes and night sweats.
- Improvement in sleep and quality of life when symptoms are menopause-related.
- Prevention of bone loss and reduction of fragility-fracture risk while used.
- Improvement in vaginal and urinary symptoms with systemic or local estrogen.
- Potential favourable risk balance for many symptomatic people under 60 or within 10 years of menopause, after individual assessment.
What are the main risks?
Risk depends on age, route, dose, duration and personal factors. Oral HRT increases venous-clot risk more than transdermal estrogen. Combined HRT slightly increases breast-cancer risk with duration, while estrogen-only HRT has a different profile.
HRT is not used to prevent cardiovascular disease or dementia. Starting at an older age or long after menopause can have a less favourable balance.
Who needs specialist advice or an alternative?
- Current or previous breast cancer or another hormone-sensitive cancer.
- Unexplained vaginal bleeding.
- Previous venous thrombosis, stroke or major cardiovascular disease.
- Severe liver disease.
- Complex migraine, premature ovarian insufficiency or treatment-induced menopause.
- Persistent symptoms despite treatment or significant medication interactions.
What is vaginal estrogen?
Low-dose vaginal estrogen treats dryness, pain, urinary symptoms and recurrent UTI tendency with minimal systemic absorption. It can often be used long term and may be combined with moisturisers or lubricants.
People with breast-cancer history need shared specialist advice, particularly when using aromatase inhibitors.
What non-hormonal options exist?
- Menopause-specific cognitive behavioural therapy for hot flushes, sleep and coping.
- Selected prescription non-hormonal medicines when HRT is unsuitable or declined.
- Vaginal moisturisers and lubricants.
- Lifestyle measures supporting sleep, bone, cardiovascular and mental health.
- Newer medicines such as neurokinin-3 receptor antagonists may be available under current indications and monitoring requirements; local availability must be verified.
What bleeding on HRT needs review?
Irregular bleeding is common soon after starting or changing HRT, but heavy, persistent, late-onset or recurrent bleeding requires a risk-based assessment.
Do not assume bleeding is harmless and do not stop or repeatedly change HRT without a plan.
Do I still need contraception?
HRT is not contraception. Contraception continues until pregnancy is no longer possible according to age, final natural period and method-specific guidance.
Some contraceptive methods can also provide the progestogen component of HRT, but suitability and licensed duration must be checked.
How is treatment reviewed?
Review after starting or changing treatment and then regularly for symptom response, side effects, bleeding, blood pressure and changing risks. Use the lowest effective dose that achieves agreed goals rather than a universal limit.
There is no mandatory age at which every patient must stop; decisions are individual.
Frequently asked questions
Do I need an FSH test?
Often not after age 45 with typical symptoms; testing is selected for younger patients or an unclear diagnosis.
Does HRT delay menopause?
No. It treats symptoms and protects bone while used but does not stop natural ovarian ageing.
Does HRT always cause weight gain?
No. Midlife weight change has many causes; HRT is not a reliable cause or weight-loss treatment.
Can HRT be used after age 60?
Sometimes, after individual review of symptoms, route, dose and risks.
Is vaginal estrogen the same as systemic HRT?
No. It uses a low local dose primarily for vaginal and urinary symptoms.
Your next step
Bring a bleeding and symptom history, medicine list, cancer and clot history and contraception needs to a menopause consultation. New postmenopausal bleeding needs assessment before assuming it is an HRT side effect.
Medical and content review: Dr Mohamed Abdelghany, Obstetrics & Gynecology Specialist, MRCOG (UK), MSc Obstetrics & Gynecology – Kasr Al-Ainy, Cairo University.
Last reviewed: 23 August 2026.
This information is for general education and does not replace individual medical assessment. Severe, sudden or concerning symptoms should not wait for a routine appointment.
